已收盘 11-13 16:00:00 美东时间
-0.880
-4.29%
11月10日,Braveheart Bio Inc.(BRVE)收涨4.62%,报19.46美元,成交额1203.29万美元,市值17.52亿美元。 行情数据...
11-10 06:31
Braveheart Bio, a clinical-stage biopharmaceutical company focused on developing therapies for hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases, announced its participation in the Jefferies Global Healthcare Conference in London, November 16-19, 2026. Management will discuss BHB-1893, a next-generation oral small-molecule cardiac myosin inhibitor, during a fireside chat on November 18, 2026. A live webcast and replay will be av...
11-09 12:30
11月7日,Braveheart Bio Inc.(BRVE)收涨6.8%,报18.6美元,成交额1263.05万美元,市值16.75亿美元。 行情数据 • 开...
11-07 06:29
The latest announcement is out from Braveheart Bio, Inc. ( ($BRVE) ). On Novemb...
11-07 04:48
11月3日,Braveheart Bio Inc.(BRVE)收跌2.19%,报21.04美元,成交额546.66万美元,市值18.94亿美元。 行情数据 •...
11-03 06:26
10月31日,Braveheart Bio Inc.(BRVE)收涨1.51%,报21.51美元,成交额1141.91万美元,市值19.37亿美元。 行情数据...
10-31 05:27
Braveheart Bio, a clinical-stage biopharmaceutical company, announced it will host an investor and analyst webinar on November 6, 2026, to discuss its cardiac myosin inhibitor program and the global clinical development of BHB-1893 for patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM). Key speakers include Anjali Owens, M.D., and Mariko Harper, M.D. A live Q&A session will follow. Interested parties can register via ...
10-30 11:30
10月27日,Braveheart Bio Inc.(BRVE)收涨2.01%,报21.87美元,成交额220.39万美元,市值19.69亿美元。 行情数据 ...
10-27 05:27
“如果你有一个好的项目,你应该第一时间就找到一个合作伙伴,共同开发全球权益,最好不要想着自己握在手里闷头研发。” 近期,在《健闻咨询》和Pivotal bio...
10-22 09:36
今日重点评级关注:BTIG:维持Rapport Therapeutics"买入"评级,目标价从75美元升至89美元;摩根士丹利:维持希捷科技"超配"评级,目标价从1187美元升至1200美元
10-21 12:30